Loading stock data…
Zai Lab Limited (ZLAB)
$25.59-0.64 (-2.44%)
Market OpenUpdated 3:21 PM EDT
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zai Lab Limited in the Healthcare sector is trading at $25.59 with a market capitalization of $2.9B. Wall Street consensus targets $33.14 (12 analysts), implying a +29.5% move over the next 12 months. The stock is currently 26% below its 52-week high of $34.72, remaining 28.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +29.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $106.31M↑ | $99.61M↓ | $127.60M↑ | $116.09M↑ | $109.98M |
| Gross Profit | $58.15M↓ | $61.28M↓ | $65.27M↓ | $69.21M↑ | $66.76M |
| Operating Income | -$76.49M↓ | -$69.28M↓ | -$68.26M↓ | -$47.97M↑ | -$54.90M |
| Net Income | -$50.83M↑ | -$51.02M↓ | -$50.41M↓ | -$35.96M↑ | -$40.73M |
Peer Comparison
JNJUNHPFE
Fundamentals
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products includ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.94B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.83
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-31.01%
Volume
Today's trading volume
572,127
Recent News
Zai Lab (ZLAB) Stock Looks Stretched On Sales But Reasonable On Broader Checks
Zai Lab stock presents a challenging valuation picture for investors, with a share price that has risen in the shorter term but sits against a five year record of heavy value loss and only a mixed read from broader valuation checks. The share price has fallen 80.9% over the past five years, which points to a significant destruction of shareholder value over a full market cycle. Future revenue growth from its biopharmaceutical portfolio can support the current valuation, while ongoing...
Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading
Asian equities traded in the US as American depositary receipts were edging lower Friday morning, de
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
Asian equities traded in the US as American depositary receipts were tracking higher Wednesday morni
Asian Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading
Asian equities traded in the US as American depositary receipts started the week lower Monday mornin
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up 2% for Week
Asian equities traded in the US as American depositary receipts were rising sharply Friday morning,